Clinical pharmacokinetics of irinotecan.

@article{Chabot1997ClinicalPO,
  title={Clinical pharmacokinetics of irinotecan.},
  author={Guy G. Chabot},
  journal={Clinical pharmacokinetics},
  year={1997},
  volume={33 4},
  pages={245-59}
}
This article reviews the clinical pharmacokinetics of a water-soluble analogue of camptothecin, irinotecan [CPT-11 or 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptoth eci n]. Irinotecan, and its more potent metabolite SN-38 (7- ethyl-10-hydroxy-camptothecin), interfere with mammalian DNA topoisomerase I and cancer cell death appears to result from DNA strand breaks caused by the formation of cleavable complexes. The main clinical adverse effects of irinotecan therapy are… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 71 extracted citations

Similar Papers

Loading similar papers…